Dishman Carbogen gains on discovering treatment for vitamin D deficiency

Dishman Carbogen Amcis Ltd (DCAL), a multinational pharmaceutical company, announced this afternoon that it has achieved successful results in its research for treatment for vitamin D deficiency.   

The company had collaborated with Boston University School of Medicine for this research, which was headed by Dr Michael Holick (Professor of Medicine at Boston University School of Medicine).  

The main aim of the research was to determine whether alternative vitamin D-type substances provide significant health benefits to people suffering from impaired distribution and metabolism of vitamin D.  

The researchers found that a form of vitamin D, also known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D. This was because vitamin D metabolite is not fat-soluble; it does not get diluted in the body fat and is effective in raising & maintaining blood levels.  

The research results will be of immense help to obese people and patients who have undergone gastric bypass surgery, which quite often results in malabsorption of vitamin D. Such patients are at a higher risk of bone diseases like osteoporosis and osteomalacia, which happens due to softening of the bones.  

This research result is a significant breakthrough for the company. Reacting to this development, the company’s stock ended Friday’s trading session in the green at Rs 193.25, up by 4.57 per cent on BSE.